Actively Recruiting

Age: 0Years - 38Years
All Genders
ID06131801

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution in Children and Young Adults With Blood Cancers

Led by Children's Hospital Medical Center, Cincinnati · Updated on 2026-06-04

30

Participants Needed

5

Research Sites

52 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the pharmacokinetics of venetoclax when tablets are crushed and dissolved into a liquid solution for children and young adults with blood cancers. This study aims to understand how the body processes venetoclax in this form, as no data currently exists for crushed tablets dissolved in liquid. The study also looks at safety, how different administration routes affect drug levels, and venetoclax concentration in the cerebrospinal fluid. Participants receive venetoclax made from crushed tablets as prescribed by their oncologist, either by mouth or through feeding tubes like nasogastric or gastrostomy tubes. Blood samples are collected at multiple time points between days 5 and 12 after dose ramp-up to measure drug clearance. Optional cerebrospinal fluid samples may also be collected around days 8, 15, 22, or 28 for additional analysis. During the study, peripheral blood is drawn to evaluate venetoclax levels, with optional cerebrospinal fluid sampling for some participants. Researchers monitor drug clearance and safety while patients continue their cancer treatment, which may include other chemotherapy drugs. The study includes patients from birth up to 38 years old, involving multiple visits to collect samples over several weeks to assess how the drug behaves in the body when given as a liquid solution.

CONDITIONS

Brief Title

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Who Can Participate

Age: 0Years - 38Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients must be younger than 39 years old at enrollment
  • Patients must have a diagnosis of any hematologic malignancy
  • Patients must have an existing venous or arterial access line for blood draws
  • Patients must weigh at least 5.5 kg at enrollment
  • Patients must be receiving venetoclax as a solution made from crushed tablets by mouth or feeding tube
  • Patients may receive venetoclax alone or with other chemotherapy drugs
Not Eligible

You will not qualify if you...

  • Pregnant women are excluded due to potential risks of venetoclax
  • Breastfeeding mothers should stop nursing if treated with venetoclax
  • Patients of reproductive potential must use effective contraception during treatment and for six months after

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Monitoring

Duration - Up to approximately 4 weeks following venetoclax dose ramp-up

Participants who receive venetoclax made from crushed tablets as part of their clinical care have peripheral blood and optional cerebrospinal fluid samples collected to evaluate pharmacokinetics.

1 intensive blood sampling day with multiple draws and up to 4 optional cerebrospinal fluid collection visits around Days 8, 15, 22, and/or 28

Trial Site Locations

Total: 5 locations

1

Children's Hospital Colorado

Aurora, Colorado, United States, 80045

Actively Recruiting

2

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States, 45229

Actively Recruiting

3

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States, 19104

Not Yet Recruiting

4

Texas Children's Hospital

Houston, Texas, United States, 77030

Actively Recruiting

5

Children's Hospital of Wisconsin

Milwaukee, Wisconsin, United States, 53226

Actively Recruiting

Loading map...

Research Team

S

Site Public Contact

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

Use of [F-18] FLT for Imaging With Positron Emission Tomogra...

Brain and Central Nervous System Tumors

Actively Recruiting

1 location

Early Phase I Evaluation of 64Cu-LLP2A for Imaging Hematolog...

Multiple Myeloma

Actively Recruiting

1 location

Exploratory Study on Allogeneic CD19/BCMA CAR-T Cell Treatme...

B Cell Lymphoma

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here